DOJ hit pharmas for $2.2 billion in 2011 False Claims Act cases

Share this article:
DOJ: Forest promoted Celexa and Lexapro off-label
DOJ: Forest promoted Celexa and Lexapro off-label
Pharmas shelled out $2.2 billion in False Claims Act fines and settlements with the Justice Department this year as the feds' healthcare fraud haul hit an all-time high.

Pharmaceutical manufacturers paid $1.76 billion to the feds and $421 million to states, accounting for nearly two-thirds of the Justice Department's $3 billion False Claims Act haul for fiscal year 2011. The drug industry's share includes the $900 million that eight manufacturers paid to resolve price-fixing charges, along with GlaxoSmithKline's $750 million settlement of civil and criminal charges “that the company knowingly submitted, or caused to be submitted, false claims to government health care programs for adulterated drugs and for drugs that failed to conform with the strength, purity or quality specified” by FDA, said DOJ.

Food, Drug and Cosmetic Act cases accounted for 21 criminal convictions and $1.3 billion in criminal fines, forfeitures, restitution and disgorgement, said DOJ, and an historic $2.8 billion came in whistle blower cases filed under the qui tam provisions of the false claims act, which were bolstered by last year's healthcare reform legislation.

“We are tremendously to whistleblowers who have brought fraud allegations to the government's attention and assisted us in this public-private partnership to fight fraud,” said Assistant Attorney General Tony West of the DOJ's Civil Division. He boasted that 28% of the recoveries in the last quarter-century came under the Obama Administration, “reflecting the extraordinary determiniation and effort that this administration and Attorney General Holder in particular have put into rooting out fraud, recovering taxpayer money and protecting the integrity of government programs.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...